Page 1 - Reflections_dyslipidaemia_newsletter4_2023

REFLECTIONS

Dyslipidaemia
Dyslipidaemia Global Newsletter #4 2023

TABLE OF CONTENTS

KEY ARTICLES
On behalf of the Scientific Planning Committee (SPC), we
Treat-to-target or high-intensity statin in patients with would like to welcome you back to the fourth newsletter in
coronary artery disease: A randomized clinical trial. Hong
SJ, et al. JAMA. 2023;329(13):1078-1087. our series where we summarize the latest clinical and real-
Dyslipida
Acute LDL-C reduction post ACS: Strike early and strike world evidence in the field of dyslipidaemia and reflect on the
strong: From evidence to clinical practice. A clinical clinical impact of these data on dyslipidaemia management. As
consensus statement of the Association for Acute always, we invite you to interact with this newsletter through
CardioVascular Care (ACVC), in collaboration with the links to podcasts, resource tools, or commentaries, or viewing
European Association of Preventive Cardiology (EAPC) short clinical perspectives from our SPC, and delve into the
and the European Society of Cardiology Working Group on articles through hyperlinks for in-depth study.
Cardiovascular Pharmacotherapy. Krychtiuk KA, et al. Eur
Heart J Acute Cardiovasc Care. 2022 Dec 27;11(12):939-949. Prof. Farnier (Chair)
Combination moderate-intensity statin and ezetimibe
therapy for elderly patients with atherosclerosis. Lee SH, et SCIENTIFIC PLANNING COMMITTEE
al. J Am Coll Cardiol. 2023;81(14):1339-1349.
Bempedoic acid and cardiovascular outcomes in
statin-intolerant patients. Nissen SE, et al. N Engl J Med. Prof. Michel Farnier Prof. Augusto Lavalle
2023;388(15):1353-1364 (France) Cobo
Association of remnant cholesterol with risk of (Argentina)
cardiovascular disease events, stroke, and mortality:
A systematic review and meta-analysis. Yang XH, et al. Prof. Miriam Sandín Prof. Lourdes Santos
Atherosclerosis. 2023;371:21-31. (Spain) (Philippines)
Lipoprotein(a) in atherosclerotic cardiovascular disease
and aortic stenosis: A European Atherosclerosis Society
consensus statement. Kronenberg F, et al. Eur Heart J. 2022 Prof. Ahmed Shawky Prof. Marcin Welnicki
Oct 14;43(39):3925-3946. (Egypt) (Poland)

ADDITIONAL ARTICLES OF INTEREST

LIPID-LOWERING TREATMENT APPROACHES IN SPECIAL POPULATIONS

Treat-to-target or high-intensity statin in patients with coronary artery disease:
A randomized clinical trial.
Hong SJ, et al. JAMA. 2023;329(13):1078-1087.

In patients with CAD, some guidelines recommend initiating with high-intensity statins to achieve ≥50% reduction in LDL-C.
Alternatively, a treat-to-target approach that begins with moderate-intensity statins and titrates to a specific LDL-C goal may be as
effective.

In this head-to-head, randomized, multicentre, non-inferiority trial, patients with CAD (n=4400) treated at 12 centres in South Korea
were randomly assigned to receive either the LDL-C target strategy (n=2200), with an LDL-C level between 50 and 70 mg/dL as the
target, or high-intensity statin treatment (n=2200), which consisted of rosuvastatin 20 mg or atorvastatin 40 mg. Non-statin add-on
therapy, such as ezetimibe, was not recommended strongly in the treat-to-target group, to focus on the strategy for choosing statin
intensity, but was used by some patients in both treatment groups. The primary endpoint was a three-year composite of death, MI,
stroke, or coronary revascularization with a non-inferiority margin of 3.0 percentage points.